| Filed On | Filing |
|---|---|
| 05 Nov 2026 | FORM 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 |
| 20 Oct 2026 |
Form 4: Bono Raquel C., Director
Received 78,800 shares as a grant or award · Granted 157,400 Stock Option (right to buy) |
| 20 Oct 2026 |
Form 3: Bono Raquel C., Director
No securities owned |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience |
| 14 Sep 2026 |
8-K: Other Events
On September 3, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), approved a Director Resignation Policy that requires a director, following certification of the stockholder vote from the meeting at which the el... |
| 25 Aug 2026 |
8-K: Other Events
On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Com... |
| 06 Aug 2026 | FORM 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027 |
| 28 Jul 2026 |
8-K: Other Events
On July 27, 2026, upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. (the “Board”) approved the reorganization of its Nominating and Governance Committee and the Compensation Commit... |
| 20 Jul 2026 |
Form 4: Finney Kevin, Director
Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy) |
| 17 Jul 2026 |
Form 4: Breitmeyer James B, Director
Received 8,315 shares as a grant or award · Granted 16,610 Stock Options (right to buy) |
| 17 Jul 2026 |
Form 4: Heron Elaine J, Director
Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy) |
| 17 Jul 2026 |
Form 4: Watson W. Mark, Director
Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy) |
| 17 Jul 2026 |
Form 4: Wheadon David E., Director
Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy) |
| 17 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., July 17, 2026 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform... |
| 07 Jul 2026 |
8-K: Other Events
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine |
| 06 Jul 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 02 Jul 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 02 Jul 2026 | DFAN14A |
Loading...